A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults

NCT00000853 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: rgp120/HIV-1MN

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)